The somatostatin analogues (SST analogues) octreotide and lanreotide improve the quality of life by providing symptomatic relief in up to 100% of cases. Unfortunately the objective response rate is low (7-28%) and the stabilization rate is about 80%. The impact on survival has not been established. Predictors of poor response are: pancreatic tumor, no previous surgery, distant extrahepatic metastases, high proliferative index (Ki675%), and weight loss. The European Neuroendocrine Tumor Society (ENET) guidelines recommend the SST analogues as first line therapy for Octreoscan-positive tumors, endocrine tumors associated with a syndrome, progressing tumors, and for the prevention of carcinoid crises during surgery. Their use after surgery, debulking, chemoembolization, and other procedures as adjuvant therapy in patients with residual disease after surgery and in the presence of asymptomatic metastases is controversial. At present, the best method is to adopt a multidisciplinary approach. Novel compounds may improve outcome in the near future.

Somatostatin analogues: The state of the art.

TOMASSETTI, PAOLA;TOMASSETTI, VINCENZO;CAMPANA, DAVIDE
2007

Abstract

The somatostatin analogues (SST analogues) octreotide and lanreotide improve the quality of life by providing symptomatic relief in up to 100% of cases. Unfortunately the objective response rate is low (7-28%) and the stabilization rate is about 80%. The impact on survival has not been established. Predictors of poor response are: pancreatic tumor, no previous surgery, distant extrahepatic metastases, high proliferative index (Ki675%), and weight loss. The European Neuroendocrine Tumor Society (ENET) guidelines recommend the SST analogues as first line therapy for Octreoscan-positive tumors, endocrine tumors associated with a syndrome, progressing tumors, and for the prevention of carcinoid crises during surgery. Their use after surgery, debulking, chemoembolization, and other procedures as adjuvant therapy in patients with residual disease after surgery and in the presence of asymptomatic metastases is controversial. At present, the best method is to adopt a multidisciplinary approach. Novel compounds may improve outcome in the near future.
Tomassetti P.; Nori F.; Piscitelli L.; Cipollini M.L.; Tomassetti V.; Campana D.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/119071
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact